Roche Holding (SWX:ROG) - Stock Price, News & Analysis

ROG Stock Overview

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally.

ROG fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 61% below our estimate of its fair value

Earnings are forecast to grow 10.51% per year

Pays a reliable dividend of 3.81%

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Roche Holding AG Competitors

Novartis

SWX:NOVN

CHF192.3b

Cosmo Pharmaceuticals

SWX:COPN

CHF648.7m

Merck

NYSE:MRK

US$267.4b

AstraZeneca

LSE:AZN

UK£173.0b

Price History & Performance

Summary of all time highs, changes and price drops for Roche Holding
Historical stock prices
Current Share Price	CHF249.10
52 Week High	CHF335.85
52 Week Low	CHF246.30
Beta	0.15
1 Month Change	-3.90%
3 Month Change	-9.34%
1 Year Change	-20.31%
3 Year Change	-22.20%
5 Year Change	3.73%
Change since IPO	854.41%

Is Roche Holding (VTX:ROG) A Risky Investment?

Aug 27

Recent updates

Shareholder Returns

	ROG	CH Pharmaceuticals	CH Market
7D	-3.1%	-1.1%	-1.3%
1Y	-20.3%	-3.0%	6.7%

Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned -3% over the past year.

Return vs Market: ROG underperformed the Swiss Market which returned 6.7% over the past year.

Price Volatility

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	2.1%
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	7.3%
10% least volatile stocks in CH Market	1.7%

Stable Share Price: ROG is less volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: ROG's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,613	Thomas Schinecker	https://www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROG fundamental statistics
Market Cap	CHF200.73b
Earnings (TTM)	CHF11.03b
Revenue (TTM)	CHF63.14b

18.0x

P/E Ratio

3.2x

P/S Ratio

Is ROG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ROG income statement (TTM)
Revenue	CHF63.14b
Cost of Revenue	CHF16.97b
Gross Profit	CHF46.17b
Other Expenses	CHF35.14b
Earnings	CHF11.03b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	13.81
Gross Margin	73.12%
Net Profit Margin	17.47%
Debt/Equity Ratio	83.7%

How did ROG perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

69%

Payout Ratio

ROG Stock Overview

Rewards

Risk Analysis

Roche Holding AG Competitors

SWX:NOVN

CHF192.3b

SWX:COPN

CHF648.7m

NYSE:MRK

US$267.4b

LSE:AZN

UK£173.0b

Price History & Performance

Recent News & Updates

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Recent updates

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Does Roche Holding (VTX:ROG) Have A Healthy Balance Sheet?

Roche Announces U.S. Food and Drug Administration Accepted Supplemental Biologics License Application for Vabysmo

Upcoming dividend of CHF9.50 per share at 3.6% yield

Roche Announces Positive New Data from Two Global phase III studies, BALATON and COMINO

Full year 2022 earnings: EPS misses analyst expectations

Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, A Rare Life-Threatening Blood Condition

Roche Holding AG Announces Executive Appointments

Roche Launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-Variant

Roche Announces the Phase III IMbrave050 Study Met Its Primary Endpoint of Recurrence-Free Survival (RFS) At the Prespecified Interim Analysis

Roche Announces the European Commission Approval of Xofluza for the Treatment and Prevention of Influenza in Children Aged One Year and Above

FDA approves Roche Holding AG’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

Roche Holding AG Announces its Alzheimer’s Disease Cerebrospinal Fluid (CSF) Assays Receive FDA Clearance, Supporting More Accurate and Timely Diagnosis

Roche Diagnostics North America Announces Brad Moore as President, Effective January 1, 2023

Roche Receives U.S. FDA Emergency Use Authorization for Its High-Throughput Test to Detect Monkeypox Virus

Roche Receives US Food and Drug Administration (FDA) Approval of VENTANA FOLR1 (FOLR1-2.1) RxDx Assay

Roche Launches Pilot Brand, Expands Retail Channels for COVID-19 at-Home Test

Roche Holding AG Announces STRONG-HF Study Results Demonstrate Clear Benefits for Acute Heart Failure Patients

Roche Introduces the navify Brand for Its Digital Health Solutions At HLTH 2022

Roche Introduces the Cobas 5800, A New Molecular Diagnostic System to Expand Access to PCR Testing in the U.S

Roche Holding AG Announces Positive Topline Results from Two Global Phase Iii Studies, BALATON and COMINO

Roche Holding Receives FDA Clearance for COVID-19 PCR Test for Use on Cobas 6800/8800 Systems

Roche Holding AG Provides Earnings Guidance for the Year 2022

Roche to Present New Ocrevus (Ocrelizumab) Data in Multiple Sclerosis and Continued Research into Neuromyelitis Optica Spectrum Disorder At Ectrims 2022

Roche Holding AG Announces New Two-Year Data from JEWELFISH Study Evaluating Evrysdi® (Risdiplam) in People with Type 1, 2 or 3 SMA Aged 6 Months to 60 Years at Time of Enrolment

Roche Launches PRAME (EPR20330) Antibody to Identify PRAME Protein Expression in Patients That May Have Melanoma

Roche Holding AG Receives FDA Approval for First Companion Diagnostic to Identify Patients with HER2 Low Metastatic Breast Cancer Eligible for Enhertu

Roche Holding AG, Annual General Meeting, Mar 14, 2023

Roche Announces Management Changes

Roche Holding AG Announces Board Changes

Roche Holding AG Grants FDA Clearance for Cobas Pure Integrated Solutions for Low- to Mid-Volume Laboratories

Roche Holding AG (SWX:ROG) entered into a merger agreement to acquire Good therapeutics, Inc. from Roche Venture Fund, RiverVest Venture Partners, LLC, Codon Capital, 3x5 Partners, LLC and Digitalis Ventures for approximately $250 million.

Roche's announces its VENTANA PD-L1 (SP263) Test Gains CE Label Expansion as Companion Diagnostic to Identify Non-Small Cell Lung Cancer Patients Eligible for Tecentriq

Roche Announces CE label expansion of the VENTANA PD-L1

Roche Holding AG Launches Digital PCR System, aPowerful New Diagnostics Platform in the Fight Against Cancer and Other Diseases

Roche Holding AG Launches Covid-19 Test That Detects and Differentiates the Emerging Variant of Interest BA.2.75

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application by Roche Holding AG

Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to SARS-CoV-2

Roche Announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

Roche Receives FDA Approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA

Roche’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

Committee for Medicinal Products for Human Use Recommends EU Approval of Roche’S Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss

Is Roche Holding (VTX:ROG) A Risky Investment?

First quarter 2022 earnings released: EPS: CHF5.33 (vs CHF4.57 in 1Q 2021)

Roche Announces Christoph Franz Decided Not to Seek Re-Election to the Board of Directors

Shareholder Returns